Aktieanalys

OncoZenge: SEK30.2m investment agreement with Yangtian Pharma - Redeye

{newsItem.title}

Redeye Publicerad: 28 Jan 07:30

Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered a SEK30.2m investment agreement with the Chinese pharmaceutical company Yangtian Pharma. We are encouraged to see that the company has secured essential funding and believe that this agreement marks a significant milestone.

Länk till analysen i sin helhet: https://www.redeye.se/research/1069490/oncozenge-sek30-2m-investment-agreement-with-yangtian-pharma?utm_source=finwire&utm_medium=RSS

Nyheter om OncoZenge

Läses av andra just nu

Om aktien OncoZenge

Senaste nytt